Shots:
- Amgen has acquired Dark Blue Therapeutics, strengthening its early oncology discovery efforts & pipeline
- As per the deal, Amgen acquired Dark Blue Therapeutics in a transaction valued at ~$840M, integrating Dark Blue into its existing research organization
- Acquisition will add a preclinical small molecule that degrades MLLT1/3 in select acute myeloid leukemia subtypes, showing differentiated anti-cancer activity & potential to overcome resistance as a standalone or combination therapy
Ref: Amgen | Image: Dark Blue Therapeutics | Press Release
Related News: The US FDA Approves Amgen’s Uplizna (Inebilizumab-cdon) to Treat Generalized Myasthenia Gravis
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
